New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?
- 25 February 2022
- journal article
- review article
- Published by Elsevier in Journal of Cardiology
- Vol. 81 (1) , 26-32
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (16K09469, 18K08056, 21K08142, 23591062, 26461088)
This publication has 66 references indexed in Scilit:
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Effects of Carperitide on the Long-Term Prognosis of Patients With Acute Decompensated Chronic Heart Failure The PROTECT Multicenter Randomized Controlled StudyCirculation Journal, 2008
- Guanylyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor-Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the HeartCirculation, 2002
- Influence of heart rate on mortality among persons with hypertension: The Framingham StudyAmerican Heart Journal, 1993
- Expression of brain natriuretic peptide gene in human heart. Production in the ventricle.Hypertension, 1991
- Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium.Journal of Clinical Investigation, 1990
- A new natriuretic peptide in porcine brainNature, 1988
- Heart rate and cardiovascular mortality: The Framingham studyAmerican Heart Journal, 1987
- Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)Biochemical and Biophysical Research Communications, 1984